EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Editorial Comment: Central Obesity in STEMI: Beyond the Obesity Paradox

Kashif Ali Hashmi, Ammar Akhtar, Abdullah Hashmi

Pakistan Heart Journal · 2026-10-31 · 59 (5) · 1313-1316

DOI: 10.47144/phj.v59i5.4010 ↗
AbstractBibliografische Angaben

Abstract

The relationship between obesity and cardiovascular disease is more complex than body mass index (BMI) alone suggests. Contemporary cardiovascular research increasingly emphasizes adipose tissue distribution, metabolic dysfunction, and the clinical context in which obesity is assessed. In this issue of the Pakistan Heart Journal, Kumar R et al. [1] examine the prevalence and prognostic significance of central obesity among patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). In their prospective cohort of 1,099 patients, central obesity was present in 68.7%. Despite this high prevalence, the investigators did not identify an independent association between central obesity and in-hospital mortality or morbidity after adjustment for the variables included in their models. These findings are especially pertinent to Pakistan and the wider South Asian region, where cardiometabolic risk often emerges at younger ages and lower BMI values than in many Western populations. A systematic review and meta-analysis found positive associations of general and central adiposity with hypertension and cardiovascular disease in South Asian populations [2]. South Asians may also accumulate more abdominal adiposity at a given BMI, underscoring the limitations of BMI as a stand-alone indicator of cardiovascular risk [3]. The high prevalence of central obesity is among the study’s most noteworthy observations. More than two-thirds of patients presenting with STEMI exceeded the prespecified Asian-specific waist-circumference threshold. Abdominal adiposity is not merely an anthropometric characteristic; it may reflect visceral fat accumulation accompanied by insulin resistance, low-grade inflammation, endothelial dysfunction, oxidative stress, and a prothrombotic milieu. These pathways plausibly contribute to atherosclerosis and plaque vulnerability before conventional metabolic disorders become clinically apparent. The tendency toward visceral and ectopic fat accumulation at comparatively modest BMI values makes this issue particularly relevant in South Asian populations [3]. Evidence from Pakistan further illustrates why BMI and abdominal adiposity should not be treated as interchangeable. A 2024 hospital-based cross-sectional study reported associations between computed tomography (CT)-based central adiposity measures and metabolic syndrome and related cardiometabolic abnormalities [4]. Although such findings cannot establish causality or be directly extrapolated to acute STEMI outcomes, they provide a relevant local context for interpreting the burden of central obesity. The principal contribution of the present study is its focus on central rather than exclusively BMI-defined obesity. BMI does not distinguish adipose tissue from lean mass or identify the anatomical distribution of fat. Consequently, individuals with similar BMI values may have substantially different visceral fat burdens and metabolic profiles. This limitation is important when interpreting the so-called obesity paradox: apparently favorable outcomes among patients classified as obese may partly reflect exposure misclassification, differences in clinical characteristics, or residual confounding rather than a protective effect of excess adiposity [5]. Previous findings from a South Asian primary-PCI cohort highlight the complexity of this relationship. Kumar et al. reported that BMI-defined obesity was associated with lower postprocedural morbidity, driven largely by less pump failure, but with higher adjusted in-hospital mortality [6]. The divergence between morbidity and mortality associations cautions against interpreting the obesity paradox as a uniform or biologically established phenomenon. The present analysis adds a complementary perspective. In-hospital mortality was 2.8% among centrally obese patients and 2.0% among those without central obesity, while pump failure occurred in 5.6% and 8.4%, respectively [1]. Neither comparison reached statistical significance. These findings do not demonstrate equivalence between groups; rather, they indicate that this cohort did not provide sufficient evidence of a difference in these short-term outcomes. Central adiposity alone may therefore have limited discriminatory value for immediate prognosis after STEMI treated with primary PCI. In contrast, several clinical and metabolic indicators were associated with in-hospital mortality in the adjusted analysis, including higher Killip class, elevated admission glucose, hypertension, diabetes, and multivessel coronary disease. Killip class III/IV showed a particularly strong association (adjusted odds ratio, 12.4). These findings suggest that acute hemodynamic compromise, metabolic disturbances, and coronary disease burden may be more informative than a single anthropometric classification when assessing immediate risk. However, the precision of these estimates should be considered in light of the limited number of deaths. Several methodological considerations warrant emphasis. First, waist circumference is an accessible and inexpensive proxy for abdominal adiposity, but it cannot distinguish visceral from subcutaneous fat. Because these compartments differ in metabolic characteristics, their combination within a single waist-based category may obscure biologically meaningful associations. CT, magnetic resonance imaging, and validated ultrasound approaches can characterize fat distribution more directly, although they are generally impractical for routine assessment during acute STEMI care. Second, central and general obesity overlapped substantially. Mean BMI was 29.5 kg/m² among centrally obese patients versus 23.0 kg/m² among those without central obesity, and 72.7% of centrally obese participants also met the study definition of general obesity. The reported adjusted odds ratio of 4.38 for the association between these classifications underscores their relationship, but does not by itself establish problematic multicollinearity in a mortality model. Future analyses should formally evaluate collinearity and consider continuous BMI and waist-circumference measures, waist-to-height ratio, and clinically meaningful combinations of adiposity phenotypes. Third, only 28 in-hospital deaths occurred, including 21 among centrally obese patients and seven among those without central obesity. This small event count limits statistical precision, especially in multivariable models containing several predictors, and increases the possibility of unstable estimates or overfitting. The absence of a statistically significant association should therefore not be interpreted as proof that a modest effect is absent. Larger multicenter studies with adequate event counts, prespecified adjustment strategies, and confidence intervals are needed. Fourth, the analysis was restricted to in-hospital outcomes. Central adiposity may exert its most important cardiovascular effects over years through metabolic and vascular pathways. Findings during the index hospitalization therefore cannot establish whether central obesity predicts recurrent infarction, heart failure, or cardiovascular death after discharge. Short-term prognostic neutrality, even if confirmed, would not negate the importance of abdominal adiposity for long-term cardiovascular prevention [2,3]. Clinically, the results should not be taken as a reason to deprioritize obesity assessment or management. Waist circumference can complement BMI and established risk indicators, including blood pressure, glycemic status, lipid profile, smoking, family history, and physical activity. At the same time, its value for long-term risk stratification should be distinguished from its incremental predictive value for mortality during an acute STEMI admission. The high burden of central obesity in this cohort strengthens the rationale for prevention efforts before the first coronary event. The findings also invite consideration of secondary prevention after STEMI. Management should prioritize guideline-directed cardiovascular care and sustained control of modifiable risk factors. Weight-management interventions, including pharmacotherapy when indicated, may be appropriate for selected patients, but decisions should depend on individual comorbidities, eligibility, and the evidence applicable to the intervention; the present observational analysis does not test any obesity treatment. For Pakistan, affordable population-level prevention remains a priority. Waist-circumference assessment, alongside blood pressure, glucose, and lipid evaluation, may help identify individuals who would benefit from comprehensive cardiovascular risk assessment. However, the effectiveness and cost-effectiveness of any community screening program should be established rather than assumed, particularly in settings with limited resources. Future multicenter Pakistani registries should collect standardized waist circumference, BMI, waist-to-height ratio, metabolic measures, and, where feasible, direct assessments of visceral adiposity. They should also document treatments, disease severity, lifestyle factors, and follow-up outcomes. Prespecified analyses of recurrent myocardial infarction, heart failure hospitalization, repeat revascularization, and cardiovascular mortality could clarify whether adiposity phenotypes have prognostic relevance beyond the index admission. Adequate event counts and careful confounder adjustment will be essential. In conclusion, this study contributes to the evolving understanding of adiposity phenotypes in South Asian patients with acute coronary syndromes. Its central message is not that abdominal obesity is harmless, but that a high prevalence of central obesity does not necessarily translate into a detectable independent association with in-hospital outcomes after STEMI and primary PCI. Immediate prognosis appears more closely associated with clinical severity and metabolic and coronary disease burden in this cohort, although limited statistical precision warrants caution. Moving beyond the simplistic question of whether obesity is protective or harmful requires attention to fat distribution, metabolic phenotype, disease stage, and duration of follow-up. This distinction is particularly important in South Asia, where abdominal adiposity and premature coronary disease remain major concerns. References Kumar R, Rai L, Raza SA, Akhtar B, Ram J, Shahid MO, et al. Central Obesity in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Prevalence, Clinical Correlates, and In-Hospital Outcomes. Pak Heart J. 2026;59(05):1305-1312. DOI: 10.47144/phj.v59i5.3161 Re F, Oguntade AS, Bohrmann B, Bragg F, Carter JL. Associations of general and central adiposity with hypertension and cardiovascular disease among South Asian populations: a systematic review and meta-analysis. BMJ Open. 2023;13(12):e074050. DOI: 10.1136/bmjopen-2023-074050 Deshpande A, Shah NS, Kandula NR. Obesity and cardiovascular risk among South Asian Americans. Curr Cardiovasc Risk Rep. 2023;17(3):73-82. DOI: 10.1007/s12170-023-00714-5 Hussain Z, Habib A, Sajjad Z. Prevalence of metabolic syndrome and its association with CT-based central adiposity measures: a cross-sectional study at a tertiary care hospital in Pakistan. BMJ Open. 2024;14(7):e082095. DOI: 10.1136/bmjopen-2023-082095 Liu SH, Lin YZ, Han S, Jin YZ. The obesity paradox in ST-segment elevation myocardial infarction patients: a meta-analysis. Ann Noninvasive Electrocardiol. 2023;28(2):e13022. DOI: 10.1111/anec.13022 Kumar R, Mujtaba M, Ahmed R, Samad M, Sapna, Ahmed S, et al. Obesity paradox: a myth or reality, time to reveal the fact in a South Asian cohort presenting with STE-ACS undergoing primary percutaneous coronary intervention. Open Heart. 2023;10(1):e002260. DOI: 10.1136/openhrt-2023-002260

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →